117TH CONGRESS  
2D Session  

H. R. 6519  

To amend the Federal Food, Drug, and Cosmetic Act regarding the patient medication information required to be included in the labeling of prescription drugs, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES  

JANUARY 28, 2022  

Mr. GOLDEN (for himself, Mr. CARTER of Georgia, Mr. RUPPERSBERGER, and Mr. WESTERMAN) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL  

To amend the Federal Food, Drug, and Cosmetic Act regarding the patient medication information required to be included in the labeling of prescription drugs, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Patients’ Right to Know Their Medication Act of 2022”.

SEC. 2. FINDINGS.

Congress finds the following:
(1) Prescription medications are important to the health and well-being of the American public.

(2) According to the Centers for Disease Control and Prevention (CDC), 48.9 percent of Americans used at least one prescription drug in the past 30 days.

(3) The utilization of prescription drugs can subject patients to adverse drug events; therefore, patient safety is of the utmost importance.

(4) Studies indicate that paper format patient medication information (PMI) can help protect patients and prevent the majority of costly adverse drug events.

(5) In addition to bolstering patient safety, the mandatory use of a standardized PMI provided to all patients in nonhospital settings could reduce costs associated with emergency room visits and hospital admissions related to adverse drug events by $14.6 to $26.2 billion dollars annually.

(6) Many patients cannot access electronic versions of PMI, thereby necessitating a paper option.

(7) The Government Accountability Office found that relying on electronic labeling as a com-
plete substitute for paper labeling could adversely impact public health.

(8) A congressionally mandated paper PMI is needed because no standardized PMI in a single page, paper copy, proven patient-friendly format is currently available to patients or required by the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.).

SEC. 3. PATIENT MEDICATION INFORMATION FOR PRESCRIPTION DRUGS.

(a) In General.—Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by inserting after section 505G (21 U.S.C. 355h) the following:

“SEC. 505H. PATIENT MEDICATION INFORMATION FOR PRESCRIPTION DRUGS.

“(a) In General.—The Secretary shall issue regulations on the patient medication information that is required to be in the printed labeling of drugs subject to section 503(b)(1), including regulations regarding the authorship, content, format, color, printing, and dissemination requirements for such patient medication information. The Secretary shall issue final regulations pursuant to the preceding sentence not later than 1 year after the date of enactment of this section.
“(b) CONTENT.—The regulations promulgated under subsection (a) shall require that the patient medication information with respect to a drug—

“(1) be scientifically accurate, include relevant patient safety information, and be approved by the Secretary;

“(2) include understandable plain language, and include graphics and pictures when applicable, and be provided in a consistent, standardized format and color for all drug products, and not be promotional in tone or content, and contain at least—

“(A) the established name of the drug (or, if the drug is a biological product, the proper name of the biological product) and the national drug code for the drug;

“(B) indications for use approved by the Food and Drug Administration;

“(C) general directions for proper use;

“(D) contraindications, warnings, precautions, the most frequently occurring adverse reactions, and adverse reactions that are important for other reasons (such as because they are serious), especially with respect to certain sub-populations such as children, pregnant women, and the elderly;
“(E) measures patients may be able to take, if any, to reduce the side effects and risks of the drug;

“(F) information about when a patient should contact his or her health care professional;

“(G) instructions not to share medications, and, if applicable, key storage requirements and recommendations relating to proper disposal of any unused portion of the drug;

“(H) known clinically important interactions with other drugs, food, and other substances;

“(I) a statement of whether sufficient data are available concerning the use of the drug in specified subpopulations, such as women, pregnant women, lactating women, women and men of reproductive age, and pediatric, geriatric, racial, and ethnic minority groups;

“(J) the name of the manufacturer and a toll-free telephone number for consumers to contact the manufacturer of the drug; and

“(K) a current link to Form FDA 3500B for voluntary reporting for consumers of ad-
verse events, product problems, and product use errors (or any successor form); and

“(3) be provided to a patient or agent of a patient in a printed format with each prescription dispensed, such that a drug labeled for distribution shall be accompanied by printed labeling physically on or within the packaging from which the drug is to be dispensed, in an adequate supply of printed patient medication information to accommodate prescriptions dispensed therefrom.

“(c) Timeliness, Consistency, Accuracy, and Effectiveness.—The regulations promulgated under subsection (a) shall—

“(1) provide for timely reviews, approvals, and updates of patient medication information as new drugs and new information become available;

“(2) provide for updates when appropriate to help communicate information that is shared by similar products or drugs within classes of medication to avoid patient confusion and harm;

“(3) include specifications for language, graphics, format, color, and pictures required by subsection (b)(2), to be developed based upon documented patient research with one or more actual drug products that demonstrates improved patient
learning and understanding of safe and effective
medication use; and

“(4) be based on a demonstrated causal connec-
tion between the enhanced patient medication infor-
mation required by the regulations and improved pa-
tient medication adherence and compliance for the
purpose of reducing the cost of health care and im-
proving desired medical outcomes.”.

(b) MISBRANDING OFFENSE.—Section 502 of the
is amended by adding at the end the following:

“(gg) If it is a drug subject to section 503(b)(1) and
patient medication information is not provided in accord-
ance with section 505H.”.